Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study
Liver International · 2023-09 · 43 (9) · 1871-1878
DOI: 10.1111/liv.15637 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Liver International, online erschienen am 08.06.2023. Verfasst von Maria Pokorska-Śpiewak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Sofosbuvir, Hepatitis C, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims The aim of this non‐commercial, open‐label, real‐life, non‐randomized clinical trial was to analyse the efficacy and safety of a pangenotypic regimen sofosbuvir/velpatasvir (SOF/VEL) in patients aged 6–18 years with chronic hepatitis C virus (HCV) infection. Methods Fifty patients qualified for the 12‐week treatment were divided into two weight groups: 15 children weighting between 17 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
- Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland.
- Department of Neurofarba, Meyer Children's University of Florence, Florence, Italy.
ORCID-Profile: Maria Pokorska-Śpiewak, Giuseppe Indolfi
Zitieren
APA
Pokorska-Śpiewak, M., Talarek, E., Aniszewska, M., Pluta, M., Dobrzeniecka, A., Marczyńska, M., & Indolfi, G. (2023). Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study. Liver International, 43(9), 1871-1878. https://doi.org/10.1111/liv.15637
Vancouver
Pokorska-Śpiewak M, Talarek E, Aniszewska M, Pluta M, Dobrzeniecka A, Marczyńska M, et al. Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study. Liver International. 2023;43(9):1871-1878. doi:10.1111/liv.15637
BibTeX
@article{Pokorskapiewak2023,
author = {Pokorska-Śpiewak, Maria and Talarek, Ewa and Aniszewska, Małgorzata and Pluta, Magdalena and Dobrzeniecka, Anna and Marczyńska, Magdalena and Indolfi, Giuseppe},
title = {Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study},
journal = {Liver International},
year = {2023},
volume = {43},
number = {9},
pages = {1871--1878},
doi = {10.1111/liv.15637}
}
EUVIMED